Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C, Ayala R, Bilbao-Sieyro C, Chillón MC, Larráyoz MJ, Soria E, Aparicio-Pérez C, Bergua JM, Bernal T, Gil C, Tormo M, Algarra L, Alonso-Domínguez JM, Rodriguez-Arbolí E, Martínez-Sanchez P, Oliva A, Colorado-Araujo AM, Rodríguez-Medina C, Vives S, Hermosín L, Martínez-López J, García-Sanz R, Pérez-Simón JA, Calasanz MJ, Gómez-Casares MT, Barragán E, Sánchez-García J J, Montesinos P. De la Torre EP, et al. Among authors: vives s. Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2023.284601. Online ahead of print. Haematologica. 2024. PMID: 38634126 Free article.
Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study.
Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M. Heald JS, et al. Among authors: vives s. Blood Adv. 2024 Mar 27:bloodadvances.2023012479. doi: 10.1182/bloodadvances.2023012479. Online ahead of print. Blood Adv. 2024. PMID: 38536941 No abstract available.
Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Martínez-Moreno A, Gutiérrez-Agüera F, Molina O, Rodríguez-Cortez VC, Ximeno-Parpal P, Fernández-Fuentes N, Petazzi P, Beneyto-Calabuig S, Velten L, Romecin P, Casquero R, Abollo-Jiménez F, de la Guardia RD, Lorden P, Bataller A, Lapillonne H, Stam RW, Vives S, Torrebadell M, Fuster JL, Bueno C, Sarry JE, Eyras E, Heyn H, Menéndez P. Velasco-Hernandez T, et al. Among authors: vives s. Hemasphere. 2024 Feb 26;8(2):e45. doi: 10.1002/hem3.45. eCollection 2024 Feb. Hemasphere. 2024. PMID: 38435427 Free PMC article.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas M, Knopinska-Posluszny W, Piątkowska-Jakubas B, García-Álvarez F, Díez MEA, Caballero M, Martínez-Cuadrón D, Aguiar E, González-Campos J, Garrido A, Algarra L, Salamero O, de la Serna J, Sayas MJ, Perez-Encinas MM, Vives S, Vidriales B, Labrador J, Prado AI, Celebrin L, Mayer J, Brioso J, de Laiglesia A, Bergua JM, Amigo ML, Rodriguez-Medina C, Polo M, Pluta A, Cichocka E, Skarupski M, Sanz MA, Wierzbowska A, Montesinos P. Sobas M, et al. Among authors: vives s. Ann Hematol. 2024 Feb;103(2):451-461. doi: 10.1007/s00277-023-05582-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38110588 Free PMC article.
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Oñate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Avila SG, Bargay J, Ortín X, Nomdedéu JF, Esteve J, Sierra J; Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM). Oñate G, et al. Among authors: vives s. Blood Cancer J. 2023 May 5;13(1):69. doi: 10.1038/s41408-023-00839-1. Blood Cancer J. 2023. PMID: 37147301 Free PMC article.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. Simoes C, et al. Among authors: vives s. Br J Haematol. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. Epub 2023 Apr 14. Br J Haematol. 2023. PMID: 37057357 No abstract available.
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar S, Ariceta B, Agirre X, Urribarri AD, Ayala R, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martínez P, Serrano J, Simoes C, Herrera P, Calasanz MJ, Alfonso-Piérola A, Paiva B, Martínez-López J, San Miguel JF, Prósper F, Montesinos P. Villar S, et al. Among authors: vives s. Front Oncol. 2022 Nov 24;12:1054458. doi: 10.3389/fonc.2022.1054458. eCollection 2022. Front Oncol. 2022. PMID: 36505804 Free PMC article.
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ, Vridiales MB, Vazquez I, Hernández-Ruano M, Ariceta B, Aguirre-Ruiz P, Burgos L, Alignani D, Sarvide S, Villar S, Pierola AA, Prosper F, Ayala R, Martínez-López J, Bergua Burgues JM, Vives S, Perez-Simon JA, Garcia-Fortes M, Bernal Del Castillo T, Colorado M, Olave M, Rodríguez-Gutiérrez JI, Labrador J, González M, San-Miguel JF, Sanz MÁ, Montesinos P, Paiva B. Simoes C, et al. Among authors: vives s. Blood Adv. 2023 Jan 10;7(1):167-173. doi: 10.1182/bloodadvances.2022008141. Blood Adv. 2023. PMID: 36240453 Free PMC article.
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Among authors: vives s. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368
106 results